BCS 242 Lecture Notes - Lecture 14: Cerebrovascular Disease, Excitotoxicity, Transient Ischemic Attack
5 Nov 2016
School
Department
Course
Professor
Document Summary
Ad cont"d: treatment: 5 medications currently have fda approval. Ach inhibitors slow breakdown of ach by blocking ach-esterase. Mediate symptoms, but do nothing for progression of disease. Specifically alleviate non-cognitive manifestations (eg. , agitation, wandering, inappropriate behavior) Side effects: gastrointestinal: namenda (nmda/memantine): moderate-severe ad treatment acts on glutamatergic system, blocks nmda receptors. Glu is useful for memory, learning, but at high levels excitotoxicity. Not much more effective than ach inhibiting class. Small positive effect on cognitive function: timing is essential. Should be targeting patients in presymptomatic stages. Research on biomarkers, early intervention: antibodies, immunotherapy research to reduce amount of abeta. Cerebrovascular disease: disease within brain"s blood vessels: disruptions in blood supply from arteries relatively uniform, characteristic symptoms in each area. Ischemic: loss of blood flow majority of cases (~88%) Embolus: particle of blood/fat from another part of body restricting air flow. Hemorrhagic: bursting of vessel due to high bp, trauma, infection, tumor, etc.
